These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11098990)

  • 1. The use of granulocyte colony-stimulating factor in critically ill patients.
    van der Poll T
    Crit Care Med; 2000 Nov; 28(11):3758-9. PubMed ID: 11098990
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study.
    Pettilä V; Takkunen O; Varpula T; Markkola A; Porkka K; Valtonen V
    Crit Care Med; 2000 Nov; 28(11):3620-5. PubMed ID: 11098963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up.
    Trillet-Lenoir V; Green JA; Manegold C; Von Pawel J; Gatzemeier U; Lebeau B; Depierre A; Johnson P; Decoster G; Matcham J
    Eur J Cancer; 1995 Nov; 31A(12):2115-6. PubMed ID: 8562177
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group.
    Heard SO; Fink MP; Gamelli RL; Solomkin JS; Joshi M; Trask AL; Fabian TC; Hudson LD; Gerold KB; Logan ED
    Crit Care Med; 1998 Apr; 26(4):748-54. PubMed ID: 9559614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients.
    Gruson D; Hilbert G; Vargas F; Valentino R; Chene G; Boiron JM; Reiffers J; Gbikpi-Benissan G; Cardinaud JP
    Crit Care Med; 2000 Sep; 28(9):3155-60. PubMed ID: 11008974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible thyroid dysfunction with filgrastim.
    de Luis DA; Romero E
    Lancet; 1996 Dec; 348(9041):1595-6. PubMed ID: 8950916
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders].
    Kitamura K; Miyagawa K; Urabe A; Sato H; Obayashi Y; Aoki I; Takaku F; Togawa A; Shindou E; Wakabayashi Y; Ohshima T; Horikoshi A; Nomura T; Ohki I; Suzuki K; Kamakura M; Oguchi A; Toyama K; Yaguchi M; Aoki N; Kato A; Mizoguchi H; Masuda M; Irie S; Fujioka S
    Jpn J Antibiot; 1996 Dec; 49(12):1062-72. PubMed ID: 9032593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor.
    Herman AC; Boone TC; Lu HS
    Pharm Biotechnol; 1996; 9():303-28. PubMed ID: 8914196
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients.
    Hanna HA; Raad II; Hackett B; Wallace SK; Price KJ; Coyle DE; Parmley CL;
    Chest; 2003 Sep; 124(3):1030-8. PubMed ID: 12970034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Colony stimulating factors in blood formation].
    Goebel M
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():51-6. PubMed ID: 7531048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filgrastim--human granulocyte-colony stimulating factor.
    Drug Ther Bull; 1993 Apr; 31(9):33-6. PubMed ID: 7688277
    [No Abstract]   [Full Text] [Related]  

  • 12. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overwhelming diffuse psoriasis during chronic HCV infection, after peginterferon-ribavirin treatment, supported by frequent resort to filgrastim rescue.
    Sabbatani S; Manfredi R
    Braz J Infect Dis; 2010; 14(4):327. PubMed ID: 20963313
    [No Abstract]   [Full Text] [Related]  

  • 14. Sterility of unit dose syringes of filgrastim and sargramostim.
    Singh RF; Corelli RL; Guglielmo BJ
    Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
    [No Abstract]   [Full Text] [Related]  

  • 15. Lichenoid cutaneous drug reaction at injection sites of granulocyte colony-stimulating factor (Filgrastim).
    Viallard AM; Lavenue A; Balme B; Pincemaille B; Raudrant D; Thomas L
    Dermatology; 1999; 198(3):301-3. PubMed ID: 10393459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterility of repackaged filgrastim and sargramostim.
    Kleinberg ML
    Am J Health Syst Pharm; 1995 May; 52(10):1101. PubMed ID: 7544685
    [No Abstract]   [Full Text] [Related]  

  • 17. Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome.
    Vivancos J; Vila M; Serra A; Loscos J; Anguita A
    Rheumatology (Oxford); 2002 Apr; 41(4):471-3. PubMed ID: 11961184
    [No Abstract]   [Full Text] [Related]  

  • 18. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction.
    Engler RJ; Weiss RB
    Ann Allergy Asthma Immunol; 1996 Jun; 76(6):531-4. PubMed ID: 8673688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of stem cell mobilization in donors with sickle cell trait.
    Al-Khabori M; Al-Ghafri F; Al-Kindi S; Al-Riyami AZ; Al-Farsi K; Al-Huneini M; Dennison D; Al-Rawas A; Khan H; Daar S
    Bone Marrow Transplant; 2015 Feb; 50(2):310-1. PubMed ID: 25365063
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.